The Europe Age Related Macular Degeneration (AMD) Market would witness market growth of 5.0% CAGR during the forecast period (2023-2030).
The macula, a region of the retina responsible for central vision, is impacted by age-related macular degeneration (AMD), a degenerative eye condition. As a person ages, the cells in the macula suffer damage and start to die, which results in vision loss. Wet age-related macular degeneration (AMD) and dry age-related macular degeneration (AMD) are the main illness classifications. Wet AMD is less common and involves the development of abnormal blood vessels beneath the macula. In contrast, dry AMD is more prevalent and involves the creation of small, yellow deposits in the macula.
Treatment options for dry AMD include vitamin supplements and lifestyle modification to lower risk factors. To treat wet AMD, eye injections of drugs are used to prevent the development of abnormal blood vessels. This medicine, known as aberrant endothelial growth factor (anti-VEGF) therapy, stops the protein from promoting the development of abnormal blood vessels. The market is essential to solving the problem of visual loss that the senior population faces.
Nearly one in seven UK residents are expected to be over the age of 75 by 2040, according to a government assessment titled “Future of an aging population” (UK). There will be 1.42 million more homes with at least one individual who is 85 years of age or older by 2037, a rise of 161% over the previous 25 years. Over 5.5 million more people will be added to the working-age population between the ages of 50 and the state pension age (SPA), from 26% in 2012 to 34% in 2050. According to a UN assessment of France aging policy, France, like other European nations, is experiencing a steady and large rise in the population of senior people. In 2012, there were 15 million persons in France over the age of 60. In 2060, this number will increase to 24 million. It is anticipated that the market will grow because of the aging populations in these regional nations.
The Germany market dominated the Europe Age Related Macular Degeneration (AMD) Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $842 million by 2030. The UK market is exhibiting a CAGR of 4.1% during (2023 - 2030). Additionally, The France market would experience a CAGR of 5.7% during (2023 - 2030).
Based on Drug Type, the market is segmented into Aflibercept, Ranibizumab and Others. Based on Disease Type, the market is segmented into Wet and Dry. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Worldwide Age Related Macular Degeneration (AMD) Market is Projected to reach USD 13.9 Billion by 2030, at a CAGR of 5.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Biogen, Inc., Bayer AG, Apellis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Ionis Pharmaceuticals, Inc., Novartis AG, Sanofi S.A., Coherus Biosciences, Inc. and Bausch Health Companies, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Drug Type
- Aflibercept
- Ranibizumab
- Others
By Disease Type
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Biogen, Inc.
- Bayer AG
- Apellis Pharmaceuticals, Inc.
- Regeneron Pharmaceuticals, Inc.
- F.Hoffmann-La Roche Ltd.
- Ionis Pharmaceuticals, Inc.
- Novartis AG
- Sanofi S.A.
- Coherus Biosciences, Inc.
- Bausch Health Companies, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Age Related Macular Degeneration (AMD) Market, by Drug Type
1.4.2 Europe Age Related Macular Degeneration (AMD) Market, by Disease Type
1.4.3 Europe Age Related Macular Degeneration (AMD) Market, by Distribution Channel
1.4.4 Europe Age Related Macular Degeneration (AMD) Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter Five Forces Analysis
Chapter 4. Strategies deployed in Age Related Macular Degeneration (AMD) Market
Chapter 5. Europe Age Related Macular Degeneration (AMD) Market by Drug Type
5.1 Europe Aflibercept Market by Country
5.2 Europe Ranibizumab Market by Country
5.3 Europe Others Market by Country
Chapter 6. Europe Age Related Macular Degeneration (AMD) Market by Disease Type
6.1 Europe Wet Market by Country
6.2 Europe Dry Market by Country
Chapter 7. Europe Age Related Macular Degeneration (AMD) Market by Distribution Channel
7.1 Europe Hospital Pharmacy Market by Country
7.2 Europe Retail Pharmacy Market by Country
7.3 Europe Online Pharmacy Market by Country
Chapter 8. Europe Age Related Macular Degeneration (AMD) Market by Country
8.1 Germany Age Related Macular Degeneration (AMD) Market
8.1.1 Germany Age Related Macular Degeneration (AMD) Market by Drug Type
8.1.2 Germany Age Related Macular Degeneration (AMD) Market by Disease Type
8.1.3 Germany Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.2 UK Age Related Macular Degeneration (AMD) Market
8.2.1 UK Age Related Macular Degeneration (AMD) Market by Drug Type
8.2.2 UK Age Related Macular Degeneration (AMD) Market by Disease Type
8.2.3 UK Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.3 France Age Related Macular Degeneration (AMD) Market
8.3.1 France Age Related Macular Degeneration (AMD) Market by Drug Type
8.3.2 France Age Related Macular Degeneration (AMD) Market by Disease Type
8.3.3 France Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.4 Russia Age Related Macular Degeneration (AMD) Market
8.4.1 Russia Age Related Macular Degeneration (AMD) Market by Drug Type
8.4.2 Russia Age Related Macular Degeneration (AMD) Market by Disease Type
8.4.3 Russia Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.5 Spain Age Related Macular Degeneration (AMD) Market
8.5.1 Spain Age Related Macular Degeneration (AMD) Market by Drug Type
8.5.2 Spain Age Related Macular Degeneration (AMD) Market by Disease Type
8.5.3 Spain Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.6 Italy Age Related Macular Degeneration (AMD) Market
8.6.1 Italy Age Related Macular Degeneration (AMD) Market by Drug Type
8.6.2 Italy Age Related Macular Degeneration (AMD) Market by Disease Type
8.6.3 Italy Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.7 Rest of Europe Age Related Macular Degeneration (AMD) Market
8.7.1 Rest of Europe Age Related Macular Degeneration (AMD) Market by Drug Type
8.7.2 Rest of Europe Age Related Macular Degeneration (AMD) Market by Disease Type
8.7.3 Rest of Europe Age Related Macular Degeneration (AMD) Market by Distribution Channel
Chapter 9. Company Profiles
9.1 Biogen, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.1.6 SWOT Analysis
9.2 Bayer AG
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 SWOT Analysis
9.3 Apellis Pharmaceuticals, Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental Analysis
9.3.4 Research & Development Expenses
9.3.5 Recent strategies and developments:
9.3.5.1 Approvals & Trails:
9.3.6 SWOT Analysis
9.4 Regeneron Pharmaceuticals, Inc.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Research & Development Expense
9.4.4 SWOT Analysis
9.5 F. Hoffmann-La Roche Ltd.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expense
9.5.5 SWOT Analysis
9.6 Ionis Pharmaceuticals, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Research & Development Expenses
9.6.4 SWOT Analysis
9.7 Novartis AG
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Approvals & Trails:
9.7.5.2 Acquisition and Mergers:
9.7.6 SWOT Analysis
9.8 Sanofi S.A.
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expense
9.8.5 SWOT Analysis
9.9 Coherus Biosciences, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Research & Development Expenses
9.9.4 Recent strategies and developments:
9.9.4.1 Approvals & Trials:
9.9.5 SWOT Analysis
9.1 Bausch Health Companies, Inc.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expense
9.10.5 Recent strategies and developments:
9.10.5.1 Product Launches and Product Expansions:
9.10.6 SWOT Analysis
TABLE 1 Europe Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
TABLE 2 Europe Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
TABLE 3 Europe Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
TABLE 4 Europe Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
TABLE 5 Europe Aflibercept Market by Country, 2019 - 2022, USD Million
TABLE 6 Europe Aflibercept Market by Country, 2023 - 2030, USD Million
TABLE 7 Europe Ranibizumab Market by Country, 2019 - 2022, USD Million
TABLE 8 Europe Ranibizumab Market by Country, 2023 - 2030, USD Million
TABLE 9 Europe Others Market by Country, 2019 - 2022, USD Million
TABLE 10 Europe Others Market by Country, 2023 - 2030, USD Million
TABLE 11 Europe Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
TABLE 12 Europe Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
TABLE 13 Europe Wet Market by Country, 2019 - 2022, USD Million
TABLE 14 Europe Wet Market by Country, 2023 - 2030, USD Million
TABLE 15 Europe Dry Market by Country, 2019 - 2022, USD Million
TABLE 16 Europe Dry Market by Country, 2023 - 2030, USD Million
TABLE 17 Europe Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 18 Europe Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 19 Europe Hospital Pharmacy Market by Country, 2019 - 2022, USD Million
TABLE 20 Europe Hospital Pharmacy Market by Country, 2023 - 2030, USD Million
TABLE 21 Europe Retail Pharmacy Market by Country, 2019 - 2022, USD Million
TABLE 22 Europe Retail Pharmacy Market by Country, 2023 - 2030, USD Million
TABLE 23 Europe Online Pharmacy Market by Country, 2019 - 2022, USD Million
TABLE 24 Europe Online Pharmacy Market by Country, 2023 - 2030, USD Million
TABLE 25 Europe Age Related Macular Degeneration (AMD) Market by Country, 2019 - 2022, USD Million
TABLE 26 Europe Age Related Macular Degeneration (AMD) Market by Country, 2023 - 2030, USD Million
TABLE 27 Germany Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
TABLE 28 Germany Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
TABLE 29 Germany Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
TABLE 30 Germany Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
TABLE 31 Germany Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
TABLE 32 Germany Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
TABLE 33 Germany Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 34 Germany Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 35 UK Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
TABLE 36 UK Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
TABLE 37 UK Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
TABLE 38 UK Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
TABLE 39 UK Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
TABLE 40 UK Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
TABLE 41 UK Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 42 UK Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 43 France Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
TABLE 44 France Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
TABLE 45 France Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
TABLE 46 France Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
TABLE 47 France Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
TABLE 48 France Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
TABLE 49 France Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 50 France Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 51 Russia Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
TABLE 52 Russia Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
TABLE 53 Russia Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
TABLE 54 Russia Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
TABLE 55 Russia Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
TABLE 56 Russia Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
TABLE 57 Russia Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 58 Russia Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 59 Spain Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
TABLE 60 Spain Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
TABLE 61 Spain Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
TABLE 62 Spain Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
TABLE 63 Spain Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
TABLE 64 Spain Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
TABLE 65 Spain Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 66 Spain Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 67 Italy Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
TABLE 68 Italy Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
TABLE 69 Italy Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
TABLE 70 Italy Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
TABLE 71 Italy Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
TABLE 72 Italy Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
TABLE 73 Italy Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 74 Italy Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 75 Rest of Europe Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
TABLE 76 Rest of Europe Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
TABLE 77 Rest of Europe Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
TABLE 78 Rest of Europe Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
TABLE 79 Rest of Europe Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
TABLE 80 Rest of Europe Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
TABLE 81 Rest of Europe Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 82 Rest of Europe Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 83 Key Information – Biogen, Inc.
TABLE 84 Key Information – Bayer AG
TABLE 85 Key Information – Apellis Pharmaceuticals, Inc.
TABLE 86 Key Information – Regeneron Pharmaceuticals, Inc.
TABLE 87 Key Information – F. Hoffmann-La Roche Ltd.
TABLE 88 Key information – Ionis Pharmaceuticals, Inc.
TABLE 89 Key Information – Novartis AG
TABLE 90 Key Information – Sanofi S.A.
TABLE 91 Key Information – Coherus Biosciences, Inc.
TABLE 92 key information – Bausch Health Companies, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 Europe Age Related Macular Degeneration (AMD) Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting Age Related Macular Degeneration (AMD)Market
FIG 4 Porter’s Five Forces Analysis – Age Related Macular Degeneration (AMD) Market
FIG 5 Europe Age Related Macular Degeneration (AMD) Market share by Drug Type, 2022
FIG 6 Europe Age Related Macular Degeneration (AMD) Market share by Drug Type, 2030
FIG 7 Europe Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2030, USD Million
FIG 8 Europe Age Related Macular Degeneration (AMD) Market share by Disease Type, 2022
FIG 9 Europe Age Related Macular Degeneration (AMD) Market share by Disease Type, 2030
FIG 10 Europe Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2030, USD Million
FIG 11 Europe Age Related Macular Degeneration (AMD) Market share by Distribution Channel, 2022
FIG 12 Europe Age Related Macular Degeneration (AMD) Market share by Distribution Channel, 2030
FIG 13 Europe Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2030, USD Million
FIG 14 Europe Age Related Macular Degeneration (AMD) Market share by Country, 2022
FIG 15 Europe Age Related Macular Degeneration (AMD) Market share by Country, 2030
FIG 16 Europe Age Related Macular Degeneration (AMD) Market by Country, 2019 - 2030, USD Million
FIG 17 Swot Analysis: Biogen, Inc.
FIG 18 Swot Analysis: Bayer AG
FIG 19 Swot Analysis: Apellis Pharmaceuticals, Inc.
FIG 20 Swot Analysis: Regeneron Pharmaceuticals, Inc.
FIG 21 Swot Analysis: F. Hoffmann-La Roche Ltd.
FIG 22 Swot Analysis: Ionis Pharmaceuticals, Inc.
FIG 23 SWOT Analysis: Novartis AG
FIG 24 Swot Analysis: Sanofi S.A.
FIG 25 Swot Analysis: Coherus Biosciences, Inc.
FIG 26 Swot Analysis: Bausch Health Companies, Inc.